Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Apr 14, 2022 5:44pm
234 Views
Post# 34605382

Salary increases another sign the phase 1a is going well?

Salary increases another sign the phase 1a is going well?The proxy reveals a nice uptick in salaries for our executive team. Some will no doubt argue this is terribly incongruant with the share price and is another indication of a "heads we win, tails you lose" situation at TH. I suspect it has more to do with the price you have to pay for talent these days and the fact that this team has delivered on cancer and the board wants to keep everyone in place so future progress is not stymied by losing key people. My guess is that when they brought John Leasure in, they ahd to pay up and then they had to adjust incumbent executives salaries to be fair. But I really suspect they know they have something potentially quite big in cancer and they want to keep things rolling forward there without any unnecessary disruption to the executive staff. 
<< Previous
Bullboard Posts
Next >>